1 / 20

HIV Cases “What to Start”

HIV Cases “What to Start”. Dr Anton Pozniak Chelsea and Westminster Hospital London. Case-SP. A 57 year old caucasian man presented to the emergency department with progressive difficulty in swallowing over the last 4 weeks.

jed
Télécharger la présentation

HIV Cases “What to Start”

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. HIV Cases“What to Start” Dr Anton Pozniak Chelsea and Westminster Hospital London

  2. Case-SP • A 57 year old caucasian man presented to the emergency department with progressive difficulty in swallowing over the last 4 weeks. • He is hypertensive and has diet controlled diabetes and asthma and takes inhaled B2 agonists and inhaled steroids • He had seen his family practitioner who saw oral thrush and thought it was related to his diabetes/ inhalers and gave him amphotericin lozenges • He had been diagnosed with HIV a year before but had not attended any clinics as he “felt well”

  3. Case-SP • He had extensive oral thrush and had severe dysphagia • BP 145/90 mmHg • He was admitted and treated with fluconazole • Social History • Lives alone is MSM • Smokes 15 a day • Alcohol 20 units a week, no recreational drugs • Drugs • Salbutamol inhaler • Fluticasone Inhaler • Amlodopine • St Johns Wort for depression

  4. Case-SP • Labs • STD screen negative • FBC,U and Es, LFTs Normal , • Cr CL 69 mls/min, Urine protein +no glucose • CD4 33 cells/uL • VL 365000 copies/ml • Hep B immune • Hep C negative • STS negative • Resistance test and HLA B5701 awaited • Framingham 10 year risk risk 18%

  5. You decide to start ARVs 1. DHHS Guidelines, March 2012. 2. T. JAMA. 2012;304:321-333. 3. EACS Guidelines, November 2011.

  6. You decide to start ARVs What is your choice of main agent? • NNRTI • PI/r • Integrase • other

  7. Difficulties in choosing-which 3rd agent? • NNRTI- • may have transmitted dug resistance • RPV may not be effective in High viral load • Integrase • BD • and may have NRTI transmitted dug resistance • PI/r • drug interactions, • diabetes, lipids

  8. NNRTI/NRTI and Prevalence of Transmitted Drug Resistance Eacs 2011 SPREAD

  9. If you decide to give a boosted PIDrug Interactions • What Drugs have significant interactions with a boosted PI? 1 St Johns Wort 2 Fluticasone 3 Amlodopine 4 None 5 all

  10. What NRTI back bone? • AZT/3TC • ABC/3TC • TDF/FTC • DDI/3TC • OTHER

  11. Difficulties in choice of NRTI • AZT- • lipodystrophy • BD • ABC • High Viral load • Cardiovascular risk(smoker and diabetic and BP) • TDF • Renal changes, • Bone changes

  12. CVD – Do drugs matter? D:A:D: Recent and/or cumulative ARV exposure and risk of MI RR of cumulative exposure/year95%CI NRTI 1.9 1.9 RR of recent* exposureyes/no95%CI 1.5 1.5 1.2 1.2 ** 1.0 1.0 0.8 0.8 0.6 0.6 ZDV ddI ddC d4T 3TC ABC TDF # PYFU: 138,109 74,407 29,676 95,320 152,009 53,300 39,157# MI: 523 331 148 405 554 221 139 RR of cumulative exposure/year95%CI NNRTI PI† 1.2 1.13 1.1 1.0 0.9 IDV NFV LPV/RTV SQV NVP EFV # PYFU: 68,469 56,529 37,136 44,657 61,855 58,946# MI: 298 197 150 221 228 221 *Current or within past 6 months; †Approximate test for heterogeneity: p=0.02; **not shown due to low number of patients receiving ddC CVD=cardiovascular disease; ARV=antiretroviral; MI=myocardial infarction; RR=relative risk; NRTI=nucleoside reverse transcriptase inhibitor; PI=protease inhibitor; NNRTI=nonnucleoside reverse transcriptase inhibitor; PYFU=patient years of follow up Adapted from Lundgren JD, et al. CROI 2009. Oral presentation 44LB.

  13. CVD: Do drugs matter? FDA meta-analysis of abacavir and MI Mantel-Haenszel Risk Difference % (95% CI) • Meta-analysis of Phase II–IV RCTs including ABC • Mean follow up 1.6 person-years per subject • Patients: 80% male (mean age=39 years) • Limitations • Young adults, so underlying MI risk low • Other CV risk factors usually unknown • Unvalidated MIs • Some studies had a PI control group Academic Trials n=5 -0.53 0.31 1.16 NIH Trials n=5 -0.45 0.03 0.51 GSK Trials n=16 -0.43 -0.11 0.21 All Trials n=26 0.008 -0.26 0.27 CVD=cardiovascular disease; FDA=Food and Drug Administration; MI=myocardial infarction; RCTs=randomised controlled trials; CV=cardiovascular; PI=protease inhibitor -0.8 0.4 0.8 1.2 -0.4 0 Created from Ding X, et al. CROI 2011. Poster presentation 808.

  14. Chronic renal disease: ART risk factors • 6,843 patients (5,136 male), median age 43 yrs, 90.1% exposed to cART, CD4 450 cells/mm3, 21.7% hypertension, 4.9% diabetes • Median follow up 3.7 years • 2-fold increased risk if hepatitis C RNA+ Incidence: 1.05 (0.91–1.18)/100 PYFU % progressed to CKD Months ART=antiretroviral therapy; PYFU=patient years follow up; IRR=incidence rate ratio Adapted from Mocroft A, et al. AIDS. 2010;24:1667–8.

  15. Low bone density/fracture: Relationship to ART ACTG 5224 & SMART: BMD loss with ART initiation ~2-4% at 1-2 yrs1 NRTI Component Primary Analysis NNRTI/PI Component Secondary Analysis EFV TDF/FTC ATV/rtv ABC/3TC 0 0 p=.004* p=.004* p=.035* -1 -1 Spine BMD percent change from week 0 -2 -2 -3 -3 -4 -4 -5 -5 24 96 144 192 0 48 0 48 24 96 144 192 Visit Week from Randomization Visit Week from Randomization No. of subjects No. of subjects TDF/FTC 128 111 105 97 87 53 EFV 133 117 109 107 86 58 ABC/3TC 122 53 ATV/rtv 116 48 130 106 101 80 125 102 91 81 * - two-sample t-test No significant interaction of NRTI and NNRTI/PI components (p=0.63) ART=antiretroviral therapy; BMD=bone mineral density; DC=drug conservation; VS=viral suppression; NRTI=nucleoside reverse transcriptase inhibitor; NNRTI=nonnucleoside reverse transcriptase inhibitor; PI=protease inhibitor; DXA=dual-energy X-ray absorptiometry 1. Adapted from McComsey G, et al. JID. 2011;203:1791–801.

  16. Case-SP • Resistance was wild type • He starts EFV TDF FTC

  17. Case AP • 35 year old Asian women presents with • Night sweats, weight loss and cough • CXR - RUL cavity and infiltrates • AAFB - smear positive and started on RZHE • Had an HIV test and was positive CD4 was 35 cells/uL

  18. Case AP • As her CD4 was<50 cells/uL she was offered ARVs within 2 weeks of starting and tolerating her TB meds What ARV combination would you offer her? What is your choice of main agent? • NNRTI-Efavirenz • PI/r-Lopinavir/r • Integrase-Raltegravir • other

  19. Case AP • Started Efavirenz but couldn't tolerate it • What would you offer her? • NNRTI-Nevirapine • PI/r-Lopinavir/r • Integrase-Raltegravir • other

  20. Case AP • What would you offer her? • NNRTI-Nevirapine-less efficacy ? Drug interaction • PI/r-Lopinavir/r major interaction with rifampicin so switch to rifabutin or double dose lopinavir/r or high dose ritonavir 400mg bd • Integrase-Raltegravir 400 or 800mg bd • Other-4 nucleosides

More Related